Detecting Full-Length CD20 Protein for Leukemia, Lymphoma, and Autoimmune Disease

CD20 is considered a hot target for treating leukemia, lymphoma and certain autoimmune diseases. However, the unstable bioactivity and low expression titer have made it extremely difficult to locate a commercially available CD20 protein for assessment of CD20-CAR expression level, development of antibody drugs and for quality control.

In order to deal with these problems, ACROBiosystems has created the highly active, full-length multi-transmembrane CD20 proteins that are expressed by HEK293 cells and insect cells, respectively. Big and small ECD loops are carried by the active full-length CD20 proteins, binding Ofatumumab and Rituximab with high-binding affinity in an SPR system and ELISA assay—all suited for BLI, SPR, ELISA, and immunization assays.

Application

Product List

Molecule Cat. No. Host Product Description
CD20/ MS4A1 CD0-H52H3 HEK293 Human CD20/ MS4A1 Full Length Protein, His Tag
CD0-H55Ha Insect cells-HI5 Human CD20/ MS4A1 Full Length Protein, His Tag

 

Product Features

Full-Length CD20 Protein Features a Complete Conformation with Both Big and Small Loops        

Full-Length CD20 Protein has Improved Bioactivity

A) HEK293 Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.

(Left) Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL. (Right) Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E.coli) with a linear range of 78–2500 ng/mL.

(Left) Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL. (Right) Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E.coli) with a linear range of 78–2500 ng/mL.

The Bioactivity of Full-Length CD20 Protein was Validated by ELISA/SPR, and Protocols are also Provided

ELISA

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression)

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind rituximab with a linear range of 0.313–1.25 μg/mL.

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind rituximab with a linear range of 0.313–1.25 μg/mL.

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.

SPR

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression)

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).

Customers can contact ACROBiosystems to add more experimental design and application data of this product.

About ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 14, 2019 at 4:02 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2019, August 14). Detecting Full-Length CD20 Protein for Leukemia, Lymphoma, and Autoimmune Disease. News-Medical. Retrieved on October 20, 2019 from https://www.news-medical.net/whitepaper/20190814/Detecting-Full-Length-CD20-Protein-for-Leukemia-Lymphoma-and-Autoimmune-Disease.aspx.

  • MLA

    ACROBiosystems. "Detecting Full-Length CD20 Protein for Leukemia, Lymphoma, and Autoimmune Disease". News-Medical. 20 October 2019. <https://www.news-medical.net/whitepaper/20190814/Detecting-Full-Length-CD20-Protein-for-Leukemia-Lymphoma-and-Autoimmune-Disease.aspx>.

  • Chicago

    ACROBiosystems. "Detecting Full-Length CD20 Protein for Leukemia, Lymphoma, and Autoimmune Disease". News-Medical. https://www.news-medical.net/whitepaper/20190814/Detecting-Full-Length-CD20-Protein-for-Leukemia-Lymphoma-and-Autoimmune-Disease.aspx. (accessed October 20, 2019).

  • Harvard

    ACROBiosystems. 2019. Detecting Full-Length CD20 Protein for Leukemia, Lymphoma, and Autoimmune Disease. News-Medical, viewed 20 October 2019, https://www.news-medical.net/whitepaper/20190814/Detecting-Full-Length-CD20-Protein-for-Leukemia-Lymphoma-and-Autoimmune-Disease.aspx.

Other White Papers by this Supplier